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Immunotherapy of Recurrent Herpes Labialis With Squaric Acid
Herpes labialis is a common condition caused by a doublestranded DNA virus belonging to the human herpesvirus family characterized by blisters or erosions on the lips and skin around the mouth and nose. [1] [2] [3] Currently, there are no US Food and Drug Administration-approved medications for preventing herpes labialis outbreaks or prolonging the interval between outbreaks. Squaric acid dibutyl ester (SADBE) is a topical immunosensitizer that induces a delayed-type hypersensitivity response and is commonly used in the treatment of verruca vulgaris and alopecia areata. When applied to warts, SADBE is believed to incite a T-cell response and to induce the killing of virally infected cells by cytotoxic lymphocytes. This influx of lymphocytes into lesional tissue may also enhance the recognition and processing of viral antigens, leading to clonal expansion of effector cells. It is hoped that SADBE will reduce the frequency and severity of herpes labialis outbreaks through these mechanisms.
Methods | This exploratory, double-blind, randomized placebocontrolled study was conducted between November 2013 and September 2015 at Massachusetts General Hospital. Healthy adults, ages 18 to 69 years, who self-reported having 6 or more episodes of herpes labialis in the previous 12 months received a topical sensitization dose on the arm at the initial visit, and then received a topical treatment dose applied to a lesion during the first 2 herpes labialis episodes occurring at least 2 weeks after the sensitization dose. Participants were randomized 1:1:1 to receive dimethyl sulfoxide alone (placebo), 2.0%
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Letters SADBE sensitization and 0.5% SADBE treatment doses, or 2.0% SADBE sensitization, 0.2% SADBE treatment doses. The study was approved by Partners Human Research Committee institutional review board, and all participants provided their written informed consent (clinicaltrials.gov identification No. NCT01971385; trial protocol is available in the Supplement).
Results | Fifty-four patients were enrolled into the study; 43 patients had at least 1 form of contact (either in person or by phone) with research staff following the sensitizing dose and were included in the efficacy data analysis (Table) . The data analyzed involves 9 males and 34 females.
One planned primary end point was days to the next herpes labialis outbreak after the last treatment dose. However, 16 of 28 patients who received 2.0% SADBE for sensitization did not experience another outbreak and did not receive a subsequent treatment dose after sensitization. Thus, we analyzed time to next outbreak after the sensitization dose. Data from patients who never experienced a first outbreak following sensitization were censored on the last available follow-up date and Kaplan-Meier time-to-event curves were estimated and graphed ( Figure) . The median time to event for the placebo group was 40 days vs more than 122 days for the 2.0% SADBE group, which difference was highly significant (P = .009).
Aside from autosensitization dermatitis that occurred in 1 patient after being exposed to the SADBE sensitization dose for 24 hours, the only other adverse events noted were itching and redness at the sensitization site, which was seen in 13 patients who received 2.0% SADBE and 2 patients who received placebo.
Discussion | This study suggests that sensitization of patients with SADBE may be useful in preventing herpes simplex virus outbreaks. Our initial hypothesis was that treatment of an active lesion would be necessary to achieve the appropriate immunologic response, but our results suggest this additional step may not be necessary for many patients. Overall, SADBE was well tolerated by our patients.
Limitations of our study include small sample size, few recurrences of herpes labialis lesions after sensitization (limiting subsequent in-person evaluation), relatively short follow-up time, and recall bias of patient-reported number of previous outbreaks per year for subject inclusion. This Kaplan-Meier graph shows the time-to-event curve of percent of subjects without a new herpes labialis outbreaks for the indicated number of days after the sensitization dose. Circles along the curves represent censored observations. DMSO indicates dimethyl sulfoxide; SADBE, squaric acid dibutyl ester. Primary oral infection with the herpes simplex virus (HSV) typically occurs at a young age, is asymptomatic, and is not associated with significant morbidity. After primary oral infection, HSV may persist in a latent state in the trigeminal ganglion and later reactivate as the more common herpes labialis, or "cold sores." Common triggers for reactivation are well known and include ultraviolet light, trauma, fatigue, stress, and menstruation. These lesions affect up to 45 percent of the U.S. population. They classically manifest as a well-localized cluster of small vesicles along the vermilion border of the lip or adjacent skin. The vesicles subsequently rupture, ulcerate, and crust within 24 to 48 hours. Spontaneous healing occurs over seven to 10 days.
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In immunocompetent patients, herpes labialis usually is mild and self-limited. However, pain, swelling, and cosmetic concerns may prompt physician consultation. Orally administered antiviral agents, such as acyclovir (Zovirax) or valacyclovir (Valtrex), have a modest clinical benefit if initiated during the prodrome. Topical treatment with 1% penciclovir cream (Denavir) may reduce healing time and pain slightly, even if initiated after the prodrome. However, reduction in healing time with systemic or topical agents is modest.
Squaric acid dibutyl ester (SADBE) is a topical immunotherapeutic agent used in the treatment of verrucae vulgaris and alopecia areata. A study completed by Lee et al of 29 patients with recalcitrant warts demonstrated complete clearance in 69% of patients with application every 2-4 weeks. Silverberg et al showed a complete clearance in 58% of patients (n=61) when SADBE was applied 3 times weekly.
SADBE has also been used with some success in the treatment of alopecia areata. In a review of the literature, Rokhsar et al noted a 50% to 60% success rate of SADBE in use for hair re-growth in this population.
SADBE has been reported to cause eczema, lymphadenopathy, blistering, allergic contact dermatitis, skin hypopigmentation, a burning sensation after application, and systemic reactions including fever and arthralgias. A study completed by Oglio et al of eight patients treated with SADBE for warts noted only mild and well tolerated side effects of erythema, desquamation, cutaneous edema, pruritus, burning, and pain.
SADBE induces a delayed-type hypersensitivity response which in warts, is believed to induce the killing of virally infected cells by cytotoxic lymphocytes. This influx of lymphocytes into lesional tissue may also enhance the recognition and processing of viral antigens, leading to Kimball Squarex 11-26-13
clonal expansion of effector cells. It is hoped that SADBE will offer subjects a safe and effective therapeutic option to decrease the frequency and severity of future herpes labialis outbreaks through these mechanisms.
II. Hypothesis and Endpoints
Hypothesis: Squaric acid dibutyl ester will significantly decrease the frequency and severity of herpes labialis outbreaks compared to placebo.
A. Primary Endpoints:
1. Determine the effect of squaric acid on frequency and severity of herpes labialis outbreaks compared to placebo. Including: a. Days with lesions in the time period from 2-8 month after the last treatment. b. Days until first subject-reported recurrence (distinct new outbreak) after the last treatment. 2. Determine the safety and tolerability of squaric acid for the treatment of herpes labialis. Cumulative pain as determined by the sum of pain levels each day of the treated outbreaks, will also be determined B. Secondary Endpoints:
1. Change in anti-HSV-1 IgG titer before and after treatment. 2. Proportion of patients positive for PBMC anti-HSV-1 proliferative response in the final blood draw (4 months after the last treatment), and the change in the proportion after treatment as compared to before treatment. 3. Average numerical measured PBMC anti-HSV-1 proliferative response at 4 months after the last treatment, and the ratio of the numerical PBMC anti-HSV-1 proliferative response after treatment versus before treatment. 4. Proportion of patients positive for a PBMC cytotoxic response against HSV-1-infected LCL at 4 months after the last treatment, and the change in the proportion after treatment as compared to before treatment. 5. Average numerical PBMC cytotoxic response against HSV-1-infected LCL at 4 months after the last treatment, and the ratio of the numerical PBMC cytotoxic response after treatment versus before treatment.
II.
Subject Selection
Subjects will be recruited from advertisements in local newspapers, posters and Partners wide email seeking interested subjects. Interested subjects will call and undergo a preliminary eligibility screen followed by a formal screening appointment at the Clinical Unit for Research Trials in Skin (CURTIS) at the Massachusetts General Hospital, at which time the protocol will be explained in detail and informed consent, will be obtained. Subjects may also be apprised of the study by information given to primary care physicians and dermatologists at MGH so that interested subjects can contact the investigators. skin cancers who will be eligible) 6. History of organ transplantation 7. Positive-HIV status determined by history at screening or known history of any other immuno-suppressing disease. 8. Severe comorbidities (diabetes mellitus requiring insulin, CHF (EF<50% at baseline will be exclusionary) of any severity, MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease 9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. 10. Subjects who have known hypersensitivity to Squaric acid or any of its components. 11. History of recent alcohol or substance abuse (< 1 year) 12. Any condition judged by the investigator to cause this clinical trial to be detrimental to the patient. 13. History of psychiatric disease that would interfere with the patient's ability to comply with the study protocol 14. History of non-compliance with other therapies.
III. Subject Enrollment
Preliminary eligibility will be determined based on study staff interviews of interested subjects over the phone. Eligible subjects will then be scheduled for a screening visit. Kimball Squarex 11-26-13
Informed Consent
Written informed consent will be signed prior to screening evaluation and testing by a licensed physician investigator. Subjects will be informed that they may withdraw from participation in the study at any point.
Randomization
Subjects will be randomized to squaric acid 0.2% versus squaric acid 0.5% vs. placebo at the baseline visit in a 1:1:1 ratio. Randomization will be performed by a computer generated randomization table and will be blinded to study investigators and subjects.
60 subjects in total will be randomized to the three treatment groups.
V. Study procedures
All doses will be administered by topically saturating a cotton swab with the appropriate solution of drug (or no drug for placebo) in dimethylsulfoxide (DMSO), and then rolling the swab over the largest lesion then present to thoroughly wet the lesion without dripping over other areas of the skin. The solutions will be in 20 ml amber bottles. To quantify the amount of drug solution applied, the cotton swab will be weighed before and after soaking it in the study medication and after application of the drug. The difference in weight will be recorded as the mass of drug solution applied.
Screening visit 1:
Patients with herpes labialis will be screened for the study at the Massachusetts General Hospital. Those who are eligible and willing to participate will be enrolled. Our goal is 60 subjects with evaluable data. To achieve this goal, we may screen up to 100 subjects.
During the screening visit, after informed consent is obtained, subjects will undergo a medical history and physical exam, which will include vital signs and lab assessments. Patients randomized to squaric acid will be given a sensitizing dose of 2.0% SADBE dissolved in DMSO applied to skin on a single spot (approximately 5 mm diameter) in the inner upper arm. The area will be encircled with Vaseline and a bandage will be applied. Patients in placebo control group 1 will be given DMSO on a single spot on the upper inner arm. The purpose of the sensitizing dose is to induce sensitivity to SADBE, so that after a 2 week initiation period, the subjects will likely be sensitive to the immunogen SADBE and the next time they are exposed to SADBE they will develop a DTH response.
Each patient will also be given a diary containing the Patient Assessment of Disease Severity worksheet which is to be completed daily while participating in this study.
Patients will also be given a camera and will be instructed to photograph their lips daily from the time they experience any symptoms such as tingling pain, burning or itching until three days after the symptoms disappear. Patients may also use their cell phone to take daily pictures as desired.
Subjects woman who is sexually active, you must use adequate birth control while in this study and for one month after using the study medication. Adequate forms of birth control include:
• Hormonal contraceptives for at least 3 months This visit will occur upon the first appearance of a herpes labialis lesion and after waiting at least 14 days after the sensitizing dose. At this visit, the lesion will be cultured for HSV detection and for polymerase chain reaction (PCR). The viral type (e.g., HSV-1 or HSV-2) will be determined. Kimball Squarex 11-26-13 A positive result for HSV culture or HSV presence by PCR will not be required for inclusion or for continuation in the study. A pregnancy test will also be conducted.
The provider will complete a targeted physical examination and the Provider Assessment of Disease Severity worksheet.
After completion of the culture and assessment, the patient will be treated by applying the appropriate solution topically to the largest lesion then present on the lip or vermillion border of the lip. Drug will only be administered once to the patients at this time and patients will only be treated within 72 hours of the onset of symptoms.
If the first lesion appears 14 days or more after the sensitizing dose, the patient will be given the first treatment dose on the same visit after swabbing the lesion for detection of virus. If lesion appears less than 14 days after the sensitizing dose, the patient will only receive cultures, and must return again for initial treatment during a subsequent outbreak.
Visit 2 summary:
• Eligibility criteria • Targeted physical exam • Provider Assessment of Disease Severity worksheet.
• Vital Signs Safety visits. These will occur 2-4 days after the first and second treatment doses. The provider will complete a targeted physical examination and the Provider Assessment of Disease Severity worksheet. Photography will also be performed.
Visit 4:
After a period of at least 21 days after the first treatment dose and up to at most 120 days after the first treatment, at a time when the patient is experiencing one or more herpes labialis lesions, they will receive a repeat dosage of the treatment to which they have been previously randomized. Treatment will be administered to the largest lesion then present on the patient's lip or vermillion border of the lip. Prior to treatment at this visit, the provider will complete a targeted physical examination, pregnancy test when indicated, and the Provider Assessment of Disease Severity worksheet.
Patients will only be treated within 72 hours of the onset of symptoms.
Patients will only receive a maximum of two treatments in the study. If after 120 days past the first treatment the patient has not again experienced a herpes labialis lesion, the patient will not receive the second treatment dose.
Visit 4 summary:
• Targeted physical exam • Provider Assessment of Disease Severity worksheet.
• Vital Signs • Laboratory assessments including: 1. Pregnancy test • Photography • Application of squaric acid 0.2% versus squaric acid 0.5% versus placebo
Subsequent visits
The patients will be monitored every 4-6 weeks for 8 months after their last treatment.
The provider will complete a targeted physical examination and the Provider Assessment of Disease Severity worksheet at each visit. At the patient's final visit (8 months after last treatment), they will be asked to turn in their camera and daily diaries.
Quantitative measurement of anti-HSV-type-1 IgG antibodies.
Because there is no commercially available quantitative testing for HSV IgG antbodies, serum will be collected and banked at MGH and later processed.
Early termination
Subjects who meet any of the criteria will not receive study drug during the 2 nd outbreak:
• Pain of skin -severe pain, limiting self care ADL (CTCAE Grade 3) Kimball Squarex 11-26-13
• Skin ulceration -combined area of ulcers >2 cm, fullial thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to the fascia (CTCAE Grade 3)
• Intense or widespread constant pruritus, limiting self care ADL or sleep, requiring oral corticosteroid or immunosuppressive therapy (CTCAE Grade 2)
• Development of urticarial lesions requiring oral intervention (CTCAE Grade 2)
Subjects who do not receive the second treatment will continue to come for monthly followup visits to monitor the progress of their HSV.
VI. Biostatistical Analysis:
Power Analysis:
The primary efficacy endpoints will be time to recurrence after treatment and the number of days with herpes labialis lesions during the period from two to eight months after the last treatment. We believe the treatment may or may not reduce the duration or severity of the outbreaks that are treated, but will reduce the frequency and severity of subsequent outbreaks. We are allowing two months after the last treatment for the treated outbreak to resolve and the immune response caused by the treatment to fully develop.
If the treatment doubles the time to recurrence or halves the number of days with lesions, and the standard deviation of these measurements in each group is 70% of the mean values, then a group size of 11 will be required in order for P to be < 0.05. A group size of 20 allows for some attrition of patients enrolled in the study and the possibility of detecting a smaller than 2-fold difference in outcomes between treated and control groups.
VII. Potential Benefits
Subjects may or may not receive any benefit from being in the study. Their skin condition may get better, stay the same, or get worse. Information gathered from this study may help other people in the future with herpes labialis.
VIII. Risks and discomforts
Risks of Squaric Acid may include: Written informed consent will be obtained from each subject at the initiation of the screening visit. In all cases, the consent will be witnessed by an appropriate health care professional. A copy of the signed consent form will be given to the subject to keep. All efforts will be made to insure the privacy rights of the study subject. No written or oral communication will be made about any patient with anyone other than the patient, unless the patient so requests. Medical information obtained from the study may become part of the patient's permanent hospital record, subject to the confidentiality and privacy regulations of the Massachusetts General Hospital.
Data and Safety Monitoring Plan
This study is considered to be moderate risk to human subjects as the study drug is not FDA approved, but is commonly used for treatment of warts and alopecia areata. The safety contact for this study is Dr. Alexa Kimball.
The study will be monitored by the principal investigator and members of the study staff. All data relevant to the assessments outlined in this protocol will be recorded in the case report form (CRF) and the subject's sourcebook.
Adverse event reporting guidelines a. Definitions Adverse Event (AE) is any untoward medical occurrence in a subject that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not related to the investigational product.
Serious Adverse Event (SAE) is any untoward medical occurrence that:
• Results in death,
• Is life-threatening, • Requires inpatient hospitalization or prolongation of existing hospitalization, • Results in persistent or significant disability or incapacity,
• Is a congenital anomaly/birth defect, or Kimball Squarex 11-26-13
• Is another medically important condition b. Reporting and Documenting Adverse Events
All untoward medical occurrences that occur after the subject signs a consent form should be documented as an AE. The Investigator should ensure that all events that occur during the study period are recorded. All AEs should be followed until resolution or until, in the Investigator's judgment, they are chronic and stable. If an emergency situation should occur, appropriate medical measures should be taken to stabilize the subject.
Documentation of AEs includes: date and time of onset and resolution of AE, intensity, frequency, seriousness, related interventions and outcome. The Investigator must also evaluate the probability of a causal relationship of the AE to the study treatment as being: "definite, probable, possible, unlikely, or unrelated." Intensity of adverse events will be graded as mild, moderate, or severe according to the following criteria:
• Mild: symptoms that are easily tolerated and transient in nature with minimal or no impairment of normal activity • Moderate: symptoms that are poorly tolerated, are sustained, and interfere with normal activity • Severe: symptoms that are incapacitating and render the subject unable to work or participate in many or all usual activities All SAEs will be reported to the IRB according to the IRB's requirements. They will also be reported to the study sponsor and FDA according to regulatory guidelines.
X. Study Discontinuation
At any time after enrollment, a subject may be discontinued. Reasons for discontinuation of a subject from the study will include, but may not be limited to, the following:
